Obstetric complications and undifferentiated connective tissue dysplasia
Abstract The manifestations of undifferentiated connective tissue dysplasia are common in the population, especially among women of reproductive age, these conditions can adversely affect on obstetric and perinatal outcomes.
Objective. The association of genetic markers, connected with disruption of the structure and function of connective tissue, with the development of obstetric complications in patients with undifferentiated connective tissue dysplasia was studyied.
Material and methods. 300 pregnant women with varying degrees of undifferentiated connective tissue dysplasia were included. They were examined of features a current gestation and gene polymorphisms of IL10, IL6, IL1B, MMP2, MMP3, MMP9, MTHFR, VEGFA and it was determined their significance in the development of pregnancy and delivery complications.
Results. It is shown that the gestational period in patients with undifferentiated connective tissue dysplasia accompanied by the high frequency of obstetric complications. Genetic predictors encoding genes the synthesis and degradation of the connective tissue were identified, they are responsible for the occurrence of adverse outcomes in pregnant women with undifferentiated connective tissue dysplasia: C/C gene IL6: 174 C> G, G/C gene VEGFA: -634 G> C, 6A/6A gene MMP3: 1171 5A> 6A, A/A MMP9: 855 A> G.
Conclusion. The identified genes polymorphisms can be used as non-invasive markers for predicting the risk of obstetric and neonatal complications.
Keywords:undifferentiated connective tissue dysplasia, obstetric complications, gene polymorphism
Clin. Experiment. Surg. Petrovsky J. 2015. № 2. Р. 47–52.
References
1. Nechaeva G.I., Yakovlev V.M., Konev V.P. et al. Connective tissue dysplasia: major clinical syndromes, formulation of diagnosis, treatment. Lechashchiy vrach [Treating Doctor]. 2008; Vol. 2: 2–7. (in Russian)
2. Kadurina T.I., Gorbunova V.N. Connective tissue dysplasia. Saint Petersburg: Elbi-SPb, 2009: 701 р. (in Russian)
3. Cappelli S., Bellando Randone S., Martinovic D. et al. «To be or not to be» ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2012; Vol. 41: 589–98.
4. Mosca M. Mixed connective tissue diseases: new aspects of clinical picture, prognosis and pathogenesis. Isr. Med. Assoc. J. 2014; Vol. 16 (11): 725–6.
5. Razumov V.V. On the choice of the functional systems of immunity and connective tissue in general pathology. Fundamental'nye issledovaniya [Fundamental Research]. 2006; Vol. 1: 36–7. (in Russian)
6. Tani C., Carli L., Vagnani S. et al. The diagnosis and classification of mixed connective tissue disease. J. Autoimmun. 2014; Vol. 48–49: 46–9.
7. Mosca M., Tani C., Carli L., Bombardieri S. Undifferentiated CTD: a wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol. 2012; Vol. 26: 73–7.
8. Castori M., Morlino S., Ghibellini G. et al. Connective tissue, Ehlers-Danlos syndrome(s), and head and cervical pain. Am. J. Med. Genet. C. Semin. Med. Genet. 2015; Vol. 169C (1): 84–96.
9. Mosca M., Tani C., Vagnani S. et al. The diagnosis and classification of undifferentiated connective tissue diseases. J. Autoim- mun. 2014; Vol. 48–49: 50–2.
10. Sengle G., Tsutsui K., Keene D.R. et al. Microenvironmental regulation by fibrillin-1. PLoS Genet. 2012; Vol. 8: e1002425.
11. Jensen S.A., Aspinall G., Handford P.A. C-terminal propeptide is required for fibrillin-1 secretion and blocks premature assem- bly through linkage to domains cbEGF41-43. Proc Natl Acad Sci USA. 2014; Vol. 111 (28): 10155–60.
12. Zweers M.C., Dean W.B., van Kuppevelt T.H. et al. Elastic fiber abnormalities in hypermobility type Ehlers-Danlos syndrome patients with tenascin-X mutations. Clin Genet 2005; Vol. 67, N 4: 330–4.
13. Tosun A., Kurtgoz S., Dursun S., Bozkurt G. A case of Ehlers- Danlos syndrome type VIA with a novel PLOD1 gene mutation. Pediatr. Neurol. 2014; Vol. 51 (4): 566–99.
14. Deng Y., Wei S., Hu S. et al. Ehlers-Danlos syndrome type IV is associated with a novel G984R COL3A1 mutation. Mol Med Rep. 2015; Vol. 12 (1): 1119–24.
15. Sung Y.K., Chung L. Connective tissue disease-associated pulmonary arterial hypertension. Rheum. Dis Clin North Am. 2015; Vol. 41 (2): 295–313.
16. Arroyo-Avila M., Vila L.M. Cardiac tamponade in a patient with mixed connective tissue disease. J. Clin. Rheumatol. 2015; Vol. 21 (1): 42–5.
17. Trudel M., Koussa M., Pontana F. et al. Aortic dissection in pregnancy. Gynecol Obstet Fertil. 2015; Vol. 43 (5): 383–8.
18. Gromova O.A, Torshin I.Yu. Possible molecular mechanisms of the effect of magnesium deficiency and orotic acid on connective tissue dysplasia. Esteticheskaya meditsina [Aesthetic Medicine]. 2009; Vol. 8 (1): 75–83. (in Russian)
19. Churilina A.V., Moskalyuk O.N., Chalaya L.F. et al. The role of magnesium in the formation of connective tissue dysplasia (review). Sovremennaya pediatriya [Contemporary Pediatrics]. 2009; Vol. 26 (4): 44–8. (in Russian)
20. Castellino G., Capucci R., Bernardi S. et al. Pregnancy in patients with undifferentiated connective tissue disease: a prospective case-control study. Lupus. 2011; Vol. 20: 1305–11.
21. Hood L., Rowen L. The Human Genome Project: big science transforms biology and medicine. Genome Med. 2013; Vol. 5 (9): 79.
22. Utts I.A., Gorodkova E.N. Undifferentiated connective tissue dysplasia in children. Pediatriya [Pediatrics]. 2006; Vol. 87 (2): 117–9. (in Russian)